Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients

Bristol Myers Squibb Co BMY announced on Tuesday the first presentation of results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to lenvatinib or sorafenib for unresectable hepatocellular carcinoma (HCC).

Related: FDA Expands Approval For Bristol Myers Squibb’s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies.

With a median follow-up of approximately 35.2 months, treatment with Opdivo plus Yervoy demonstrated:

• A statistically significant and clinically meaningful improvement in the primary endpoint of overall survival (OS).
• Median OS was 23.7 months for Opdivo plus Yervoy compared to 20.6 months with lenvatinib or sorafenib.
• The overall survival benefit was generally consistent across patient subgroups.
• A statistically significant and clinically meaningful improvement in the key secondary endpoint of objective response rate (ORR) was 36% for Opdivo plus Yervoy compared to 13% with lenvatinib or sorafenib.
• A higher complete response (CR) rate of 7% for Opdivo plus Yervoy vs. 2% with lenvatinib or sorafenib.
• Responses were durable; among responders, the median duration of response was 30.4 months for Opdivo plus Yervoy and 12.9 months for lenvatinib or sorafenib.
• Opdivo plus Yervoy demonstrated a significantly reduced risk of symptom deterioration of 24% compared to lenvatinib or sorafenib.

Also Read: Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday?

BMY Price Action: Bristol Myers Squibb shares are down 0.12% at $41.71 at last check Tuesday.

Photo: Shutterstock